---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-024556"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-11-21T23:59:59+00:00"
generated_at: "2026-05-16T17:42:42.758564+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MAIA Biotech highlights 12 patients enrolled in THIO-101 Phase 2 expansion, 30-month survival at SITC 2025

## Summary
- 12 patients enrolled to date in Phase 2 THIO-101 expansion trial; sites now open in EMA countries, Turkey, and Taiwan.
- Phase 3 THIO-104 screening has begun; CEO cites 17.8 months median OS observed in Phase 2 as potential basis for early FDA approval.
- A patient treated in March 2023 showed survival of 30 months (912 days) as of September 17, 2025.
- Posters presented at SITC 2025 detail Phase 2 and Phase 3 trial designs for ateganosine + cemiplimab in advanced NSCLC.
- FDA has granted Fast Track designation for ateganosine in NSCLC.

## SEC filing metadata
- accession: 0001493152-25-024556
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225024556/0001493152-25-024556-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225024556/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-024556
- JSON: https://secwatch.observer/filing/0001493152-25-024556.json
- Plain text: https://secwatch.observer/filing/0001493152-25-024556.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.